Archive · 2 Jul 2025
Delhi HC Orders CDSCO Review on Weight Loss Drug Safety
A court in Delhi is looking into the safety of certain diabetes medicines (GLP-1-RA drugs) when they're used for weight loss.
Some people are worried they might not be safe enough, especially for young people.
The court has told the government agency in charge of drugs (CDSCO) to decide whether these worries are valid within three months.
The court is also concerned about the aggressive marketing of these drugs as quick fixes for weight loss and wants to ensure they are safe.
Delhi High Court instructed CDSCO to review the safety of GLP-1-RA drugs for weight management.
The court order mandates a decision from CDSCO within three months.
The PIL challenges the marketing approval of GLP-1-RA drugs for weight loss.
Concerns include potential risks such as pancreatitis and cardiovascular issues.
The petitioner points to a lack of India-specific trials and sufficient regulatory oversight.
- Who
- Delhi High Court, CDSCO, and the petitioner raising safety concerns.
- What
- Delhi High Court directs CDSCO to review the safety concerns of GLP-1-RA drugs used for weight management.
- When
- The court order was issued recently, setting a 3-month deadline.
- Where
- Delhi, India.
- Why
- Due to concerns regarding the safety, regulatory oversight, and aggressive marketing of GLP-1-RA drugs for weight loss and aesthetic purposes.
Concerns over Safety and Regulation
Potential Benefits and growing market acceptance
Safety Data
Concerns over Safety and Regulation
Concerns regarding insufficient safety data.
Potential Benefits and growing market acceptance
Potential use for weight loss and aesthetic purposes.
Marketing Practices
Concerns over Safety and Regulation
Aggressive marketing tactics.
Potential Benefits and growing market acceptance
Quick-fix solutions
Regulatory Oversight
Concerns over Safety and Regulation
Lack of transparency in clinical data.
Potential Benefits and growing market acceptance
Quick-fix solutions
- Drug Class
- GLP-1-RA
- Drugs Mentioned
- Semaglutide, Tirzepatide, Liraglutide
- Original Purpose
- Type 2 Diabetes Treatment
- Concerns Raised
- Safety, lack of Indian trials, and aggressive marketing.
- Court Action
- Directed CDSCO to review safety within 3 months
- Petitioner's Stance
- Challenging approval for weight loss use.
Sources
As anti-obesity drug Wegovy launches in India, patients share experience using drugs like Mounjaro; doctors weigh in effectiveness
‘Decide within 3 months’: Delhi HC tells CDSCO on plea against use of diabetes drugs in weight management